UK markets closed

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.4300+0.1200 (+3.63%)
At close: 06:57PM GMT
Full screen
Previous close3.3100
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range3.2213 - 3.5400
52-week range1.4800 - 13.4182
Avg. volume17,923
Market cap1.515M
Beta (5Y monthly)0.98
PE ratio (TTM)0.01
EPS (TTM)2.9670
Earnings date06 Mar 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024

    GAITHERSBURG, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, March 6, 2024, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year 2023. Emergent’s newly appointed president and CEO, Joseph C. Papa, will provide remarks. Conference Call InformationParticipants can access the conference call live via webcast from the Investors page of Emergent’s website. To participate via telephone, pl

  • Reuters

    UPDATE 2-Emergent appoints former Bausch + Lomb CEO to head company

    Emergent BioSolutions said on Wednesday it has named former Bausch + Lomb CEO Joseph Papa to the top job as the company, which makes the opioid overdose reversal drug Narcan, aims to return to revenue growth. Shares of Emergent rose more than 10% before the bell. Papa has 35 years of experience in the healthcare industry.

  • GlobeNewswire

    Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

    Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company’s debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood